{"id":338678,"date":"2026-11-04T11:36:45","date_gmt":"2026-11-04T06:06:45","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=338678"},"modified":"2026-11-04T11:36:45","modified_gmt":"2026-11-04T06:06:45","slug":"life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/","title":{"rendered":"3 Life Science and Performance Chemicals Company, Active Ingredients Leader and Generic Drugs Maker Stocks With a Strong Future Roadmap: Atul, Divi&#8217;s Laboratories and Alembic Pharmaceuticals"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Atul, Divi&#8217;s Laboratories and Alembic Pharmaceuticals: ROE of 10.9% to 15.3% and FY22 to FY26 revenue CAGR of 5.1% to 8.4%. Prices as of 3 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three life science chemical, API and drug stocks to watch are Atul, Divi&#8217;s Laboratories and Alembic Pharmaceuticals. Their return on equity ranges from 10.9% to 15.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 8.4%. Divi&#8217;s Laboratories has the highest return on equity at 15.3%, while Alembic Pharmaceuticals has the fastest revenue growth at 8.4% a year. Prices are based on the 3 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Life science chemical, API and drug stocks give investors a way to track businesses that sit close to everyday demand in India. Atul, Divi&#8217;s Laboratories and Alembic Pharmaceuticals cover a chemicals company, an active ingredients leader and a generic drugs maker.<\/p>\n<p>This list covers three life science chemical, API and drug stocks with complete current figures: Atul, Divi&#8217;s Laboratories and Alembic Pharmaceuticals. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#What_Are_Life_Science_Chemical_API_and_Drug_Stocks\" title=\"What Are Life Science Chemical, API and Drug Stocks?\">What Are Life Science Chemical, API and Drug Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#Life_Science_Chemical_API_and_Drug_Stocks_at_a_Glance\" title=\"Life Science Chemical, API and Drug Stocks at a Glance\">Life Science Chemical, API and Drug Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#Why_Do_Life_Science_Chemical_API_and_Drug_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Life Science Chemical, API and Drug Stocks Have a Strong Roadmap in India?\">Why Do Life Science Chemical, API and Drug Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#Why_Atul_Features_Among_These_Life_Science_Chemical_API_and_Drug_Stocks\" title=\"Why Atul Features Among These Life Science Chemical, API and Drug Stocks\">Why Atul Features Among These Life Science Chemical, API and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#Why_Divis_Laboratories_Features_Among_These_Life_Science_Chemical_API_and_Drug_Stocks\" title=\"Why Divi&#8217;s Laboratories Features Among These Life Science Chemical, API and Drug Stocks\">Why Divi&#8217;s Laboratories Features Among These Life Science Chemical, API and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#Why_Alembic_Pharmaceuticals_Features_Among_These_Life_Science_Chemical_API_and_Drug_Stocks\" title=\"Why Alembic Pharmaceuticals Features Among These Life Science Chemical, API and Drug Stocks\">Why Alembic Pharmaceuticals Features Among These Life Science Chemical, API and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#Atul_vs_Divis_Laboratories_vs_Alembic_Pharmaceuticals_on_Key_Financials\" title=\"Atul vs Divi&#8217;s Laboratories vs Alembic Pharmaceuticals on Key Financials\">Atul vs Divi&#8217;s Laboratories vs Alembic Pharmaceuticals on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#Key_Risks_to_Check_Before_Investing_in_Life_Science_Chemical_API_and_Drug_Stocks\" title=\"Key Risks to Check Before Investing in Life Science Chemical, API and Drug Stocks\">Key Risks to Check Before Investing in Life Science Chemical, API and Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#Final_Thoughts_on_Life_Science_Chemical_API_and_Drug_Stocks\" title=\"Final Thoughts on Life Science Chemical, API and Drug Stocks\">Final Thoughts on Life Science Chemical, API and Drug Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#What_are_life_science_chemical_API_and_drug_stocks\" title=\"What are life science chemical, API and drug stocks?\">What are life science chemical, API and drug stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#Which_life_science_chemical_API_and_drug_stocks_are_covered_in_this_list\" title=\"Which life science chemical, API and drug stocks are covered in this list?\">Which life science chemical, API and drug stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#Why_do_life_science_chemical_API_and_drug_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do life science chemical, API and drug stocks have a strong future roadmap in India?\">Why do life science chemical, API and drug stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#How_has_Atul_performed_financially\" title=\"How has Atul performed financially?\">How has Atul performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#How_has_Divis_Laboratories_performed_financially\" title=\"How has Divi&#8217;s Laboratories performed financially?\">How has Divi&#8217;s Laboratories performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#How_has_Alembic_Pharmaceuticals_performed_financially\" title=\"How has Alembic Pharmaceuticals performed financially?\">How has Alembic Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#What_risks_should_investors_check_before_buying_life_science_chemical_API_and_drug_stocks\" title=\"What risks should investors check before buying life science chemical, API and drug stocks?\">What risks should investors check before buying life science chemical, API and drug stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/life-science-and-performance-chemicals-company-active-ingredients-leader-and-generic-drugs-maker-stocks-roadmap-quayside-list\/#Is_this_list_of_life_science_chemical_API_and_drug_stocks_investment_advice\" title=\"Is this list of life science chemical, API and drug stocks investment advice?\">Is this list of life science chemical, API and drug stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Life_Science_Chemical_API_and_Drug_Stocks\"><\/span><strong>What Are Life Science Chemical, API and Drug Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Life science chemical, API and drug stocks are listed companies that make life science and performance chemicals, produce active ingredients and custom synthesis products, and sell generic formulations in the United States and branded medicines in India. Their earnings depend on global orders and approvals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Life_Science_Chemical_API_and_Drug_Stocks_at_a_Glance\"><\/span><strong>Life Science Chemical, API and Drug Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/atul\/atul-ltd-share-price-today\">Atul<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,073<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17,898<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.03<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/divislab\/divi's-laboratories-ltd-share-price-today\">Divi&#8217;s Laboratories<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10,064<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">241,311<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">82.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.00<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/aplltd\/alembic-pharmaceuticals-ltd-share-price-today\">Alembic Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">802.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14,914<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.25<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Atul and Alembic Pharmaceuticals trade at a P\/E below the industry P\/E, while Divi&#8217;s Laboratories trades above it, which reflects the growth the market already expects. Readers comparing life science chemical, API and drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in life science chemical, API and drug stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Life_Science_Chemical_API_and_Drug_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Life Science Chemical, API and Drug Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Life science chemical, API and drug stocks have a strong roadmap in India because growing demand for specialty chemicals, global pharma outsourcing and rising generic use keep widening the market for these export linked companies.<\/p>\n<ul>\n<li><strong>Chemicals.<\/strong> Crop and pharma users need specialty inputs.<\/li>\n<li><strong>Active ingredients.<\/strong> Global drug firms outsource large volumes.<\/li>\n<li><strong>Generics.<\/strong> US and Indian patients use more medicines.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Atul_Features_Among_These_Life_Science_Chemical_API_and_Drug_Stocks\"><\/span><strong>Why Atul Features Among These Life Science Chemical, API and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the life science chemical, API and drug stocks on this list, Atul is a Gujarat-based chemical company with life science chemicals for crop protection and pharmaceuticals, and performance and other chemicals that include aromatics, colours and polymers.<\/p>\n<p>In the June 2026 quarter, revenue grew 25.1% year on year to Rs 1,881 crore, while net profit rose 91.8% to Rs 254 crore. Revenue rose from Rs 5,157 crore in FY22 to Rs 6,476 crore in FY26, a compound annual growth rate of 5.9%.<\/p>\n<p>Net profit grew from Rs 507 crore in FY23 to Rs 689 crore in FY26, which works out to a compound annual growth rate of 10.8%. The company has a return on equity of 10.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 17,898 crore. The stock trades at a P\/E of 22.1, below the industry P\/E of 35.1.<\/p>\n<p><strong>Roadmap:<\/strong> The company supplies many industries from a single integrated site and has been adding capacity in higher-value chemicals. A broad product basket across agriculture, pharma and consumer uses spreads demand.<\/p>\n<p><strong>What to watch:<\/strong> Check capacity additions and demand in agrochemical and pharmaceutical intermediates.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Divis_Laboratories_Features_Among_These_Life_Science_Chemical_API_and_Drug_Stocks\"><\/span><strong>Why Divi&#8217;s Laboratories Features Among These Life Science Chemical, API and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the chemical and pharma shares on this list, Divi&#8217;s Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.<\/p>\n<p>The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P\/E of 82.5, above the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.<\/p>\n<p><strong>What to watch:<\/strong> Check the order flow in custom synthesis and the commissioning of new capacity.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Alembic_Pharmaceuticals_Features_Among_These_Life_Science_Chemical_API_and_Drug_Stocks\"><\/span><strong>Why Alembic Pharmaceuticals Features Among These Life Science Chemical, API and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.<\/p>\n<p>Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%.<\/p>\n<p>In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P\/E of 21.6, below the industry P\/E of 35.7.<\/p>\n<p><strong>Roadmap:<\/strong> The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.<\/p>\n<p><strong>What to watch:<\/strong> Follow new approvals in the United States, the pace of complex generic launches and domestic growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Atul_vs_Divis_Laboratories_vs_Alembic_Pharmaceuticals_on_Key_Financials\"><\/span><strong>Atul vs Divi&#8217;s Laboratories vs Alembic Pharmaceuticals on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three life science chemical, API and drug stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Atul<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,157<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6,476<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">689<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Divi&#8217;s Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,074<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11,067<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,568<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.2%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Alembic Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,356<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,399<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">671<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.1%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Divi&#8217;s Laboratories posts the highest return on equity in this group at 15.3%. Divi&#8217;s Laboratories has the largest FY26 revenue at Rs 11,067 crore, and Alembic Pharmaceuticals shows the fastest revenue growth with a 8.4% compound annual rate. A useful habit with life science chemical, API and drug stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several aromatics, ingredient and formulation stocks instead of one name, which keeps a single result from deciding the outcome.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Atul<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,504<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,881<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Divi&#8217;s Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,529<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,144<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Alembic Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,717<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,165<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">26.1%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Life_Science_Chemical_API_and_Drug_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Life Science Chemical, API and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these life science chemical, API and drug stocks, the main points are: Long-term chemical and pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Raw material and energy costs.<\/strong> Input prices can move margins in chemicals.<\/li>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter life science chemical, API and drug stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Life_Science_Chemical_API_and_Drug_Stocks\"><\/span><strong>Final Thoughts on Life Science Chemical, API and Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Life science chemical, API and drug stocks work best when investors track growth, valuation and return on equity side by side. Atul, Divi&#8217;s Laboratories and Alembic Pharmaceuticals each have a clear plan to grow. Based on the 3 November 2026 close, Atul trades at Rs 5,073, Divi&#8217;s Laboratories at Rs 10,064 and Alembic Pharmaceuticals at Rs 802.8. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these life science chemical, API and drug stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track life science chemical, API and drug stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_life_science_chemical_API_and_drug_stocks\"><\/span><strong>What are life science chemical, API and drug stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Life science chemical, API and drug stocks are listed companies that make life science and performance chemicals, produce active ingredients and custom synthesis products, and sell generic formulations in the United States and branded medicines in India. Their earnings depend on global orders and approvals. This list looks at three of them, Atul, Divi&#8217;s Laboratories and Alembic Pharmaceuticals, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_life_science_chemical_API_and_drug_stocks_are_covered_in_this_list\"><\/span><strong>Which life science chemical, API and drug stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Atul, Divi&#8217;s Laboratories and Alembic Pharmaceuticals. Based on the 3 November 2026 close, Atul traded at Rs 5,073, Divi&#8217;s Laboratories at Rs 10,064 and Alembic Pharmaceuticals at Rs 802.8. Their return on equity ranges from 10.9% to 15.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 8.4%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_life_science_chemical_API_and_drug_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do life science chemical, API and drug stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Life science chemical, API and drug stocks have a strong roadmap in India because growing demand for specialty chemicals, global pharma outsourcing and rising generic use keep widening the market for these export linked companies. The main drivers are as follows. Chemicals. Crop and pharma users need specialty inputs. Active ingredients. Global drug firms outsource large volumes. Generics. US and Indian patients use more medicines. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Atul_performed_financially\"><\/span><strong>How has Atul performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,157 crore in FY22 to Rs 6,476 crore in FY26, a compound annual growth rate of 5.9%. Net profit grew from Rs 507 crore in FY23 to Rs 689 crore in FY26, which works out to a compound annual growth rate of 10.8%. In the June 2026 quarter, revenue grew 25.1% year on year to Rs 1,881 crore, while net profit rose 91.8% to Rs 254 crore. The company has a return on equity of 10.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 17,898 crore. The stock trades at a P\/E of 22.1, below the industry P\/E of 35.1. Looking ahead, the company supplies many industries from a single integrated site and has been adding capacity in higher-value chemicals. A broad product basket across agriculture, pharma and consumer uses spreads demand.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Divis_Laboratories_performed_financially\"><\/span><strong>How has Divi&#8217;s Laboratories performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P\/E of 82.5, above the industry P\/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Alembic_Pharmaceuticals_performed_financially\"><\/span><strong>How has Alembic Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P\/E of 21.6, below the industry P\/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_life_science_chemical_API_and_drug_stocks\"><\/span><strong>What risks should investors check before buying life science chemical, API and drug stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying life science chemical, API and drug stocks. Raw material and energy costs. Input prices can move margins in chemicals. Regulatory approvals. Plant inspections and approvals can affect supplies. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_life_science_chemical_API_and_drug_stocks_investment_advice\"><\/span><strong>Is this list of life science chemical, API and drug stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are life science chemical, API and drug stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Life science chemical, API and drug stocks are listed companies that make life science and performance chemicals, produce active ingredients and custom synthesis products, and sell generic formulations in the United States and branded medicines in India. Their earnings depend on global orders and approvals. This list looks at three of them, Atul, Divi's Laboratories and Alembic Pharmaceuticals, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which life science chemical, API and drug stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Atul, Divi's Laboratories and Alembic Pharmaceuticals. Based on the 3 November 2026 close, Atul traded at Rs 5,073, Divi's Laboratories at Rs 10,064 and Alembic Pharmaceuticals at Rs 802.8. Their return on equity ranges from 10.9% to 15.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 8.4%.\"}},{\"@type\":\"Question\",\"name\":\"Why do life science chemical, API and drug stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Life science chemical, API and drug stocks have a strong roadmap in India because growing demand for specialty chemicals, global pharma outsourcing and rising generic use keep widening the market for these export linked companies. The main drivers are as follows. Chemicals. Crop and pharma users need specialty inputs. Active ingredients. Global drug firms outsource large volumes. Generics. US and Indian patients use more medicines. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Atul performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,157 crore in FY22 to Rs 6,476 crore in FY26, a compound annual growth rate of 5.9%. Net profit grew from Rs 507 crore in FY23 to Rs 689 crore in FY26, which works out to a compound annual growth rate of 10.8%. In the June 2026 quarter, revenue grew 25.1% year on year to Rs 1,881 crore, while net profit rose 91.8% to Rs 254 crore. The company has a return on equity of 10.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 17,898 crore. The stock trades at a P\/E of 22.1, below the industry P\/E of 35.1. Looking ahead, the company supplies many industries from a single integrated site and has been adding capacity in higher-value chemicals. A broad product basket across agriculture, pharma and consumer uses spreads demand.\"}},{\"@type\":\"Question\",\"name\":\"How has Divi's Laboratories performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P\/E of 82.5, above the industry P\/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.\"}},{\"@type\":\"Question\",\"name\":\"How has Alembic Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P\/E of 21.6, below the industry P\/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying life science chemical, API and drug stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying life science chemical, API and drug stocks. Raw material and energy costs. Input prices can move margins in chemicals. Regulatory approvals. Plant inspections and approvals can affect supplies. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of life science chemical, API and drug stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Life Science Chemical, API and Drug Stocks with a strong future roadmap: Atul, Divi&#8217;s Laboratories and Alembic Pharmaceuticals. Compare price, valuation, return on equity and revenue growth as of 3 November 2026.<\/p>\n","protected":false},"author":34,"featured_media":338677,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[10050,19685,19687,10040,3803,19686,457,19688,19684],"class_list":["post-338678","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-alembic-pharmaceuticals","tag-api-and-drug-stocks","tag-aromatics","tag-atul","tag-best-stocks","tag-chemical-and-pharma-shares","tag-divis-laboratories","tag-ingredient-and-formulation-stocks","tag-life-science-chemical"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["338677"],"rank_math_title":["Chemical, API and Generic Drug Stocks"],"rank_math_description":["Compare 3 life science chemical, API and drug stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 3 Nov 2026."],"rank_math_focus_keyword":["life science chemical, API and drug stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-life-science-and-performance-chemicals-company-active-ingredients-leader-and.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/338678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=338678"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/338678\/revisions"}],"predecessor-version":[{"id":338679,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/338678\/revisions\/338679"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/338677"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=338678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=338678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=338678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}